Development in genetic technology has led to the identification of an increasing number of genes associated with epilepsy. These discoveries will both provide the basis for including genetic tests in clinical practice and improve diagnosis and treatment of epilepsy. By searching through several databases (OMIM, HGMD, and EpilepsyGene) and recent publications on PubMed, we found 977 genes that are associated with epilepsy. We classified these genes into 4 categories according to the manifestation of epilepsy in phenotypes. We found 84 genes that are considered as epilepsy genes: genes that cause epilepsies or syndromes with epilepsy as the core symptom. 73 genes were listed as neurodevelopment-associated genes: genes associated with both brain-development malformations and epilepsy. Several genes (536) were epilepsy-related: genes associated with both physical or other systemic abnormalities and epilepsy or seizures. We found 284 additional genes putatively associated with epilepsy; this requires further verification. These integrated data will provide new insights useful for both including genetic tests in the clinical practice and evaluating the results of genetic tests. We also summarized the epilepsy-associated genes according to their function, with the goal to better characterize the association between genes and epilepsies and to further understand the mechanisms underlying epilepsy.
Introduction
Advances in genomics techniques, especially the development of next-generation sequencing, have greatly increased our knowledge on the genetic changes occurring across the entire human genome, allowing for rapid and efficient discovery of genes involved in many diseases. Epilepsies may result from primary genetic abnormalities or secondary to well-defined structural or metabolic disorders, of which, some also have genetic causes. It is estimated that more than half of epilepsies have a genetic basis [1] . The application of genomic technologies has a tremendous impact on the discovery of the genetic basis of epilepsy, and it is expected to play a pivotal role in the diagnosis and treatment of epilepsy. However, epilepsies associated with genetic abnormalities display large heterogeneity. Mutations in some genes may selectively cause epilepsies or syndromes with epilepsy as the core symptom (e.g., SCN1A mutations cause epilepsies with febrile seizures plus [2] ), while other genes may be associated with gross brain developmental malformations and epilepsies (e.g., mutations in TSC1 and TSC2 genes cause tuberous sclerosis [3, 4] ). Seizures may also occur in other genetic disorders affecting the central nervous system, such as Fragile X Syndrome [5] and myoclonus-dystonia [6] . Therefore, it is a challenge to decide which gene, or group of genes, should be characterized in a specific target patient population before designing an efficient and cost-effective genetic-testing strategy. In this review, we present a summary of the genes associated with epilepsy. We grouped the genes according to the manifestation of epilepsy in the phenotype, i.e., whether epilepsy is the exclusive outcome of the mutation or part of a group of unrelated symptoms. The aim of the present review is to offer an insight into the genes that should be included in the genetic testing of patients with a distinct phenotype. The association between genes and epilepsy will further our Bold italics, with multiple epilepsy phenotypes. AD, autosomal dominant; AR, autosomal recessive; UN, unknown; XL, X-linked; XLD, X-linked dominant; XLR, X-linked recessive. AARS, alanyl-tRNA synthetase; ADRA2B, alpha-2B-adrenergic receptor; ALDH7A1, aldehyde dehydrogenase 7 family, member A1; ALG13, asparagine-linked glycosylation 13, S. cerevisiae, homolog of; ARHGEF9, RHO guanine nucleotide exchange factor 9; ARV1, ARV1, S. cerevisiae, homolog of; CACNA1A, calcium channel, voltage-dependent, P/Q type, alpha-1A subunit; CACNA1H, calcium channel, voltage-dependent, T type, alpha-1H subunit; CACNB4, calcium channel, voltage-dependent, beta-4 subunit; CASR, calciumsensing receptor; CDKL5, cyclin-dependent kinase-like 5; CERS1, ceramide synthase 1; CHD2, chromodomain helicase DNA-binding protein 2; CHRNA2, cholinergic receptor, neuronal nicotinic, alpha polypeptide 2; CHRNA4, cholinergic receptor, neuronal nicotinic, alpha polypeptide 4; CHRNB2, cholinergic receptor, neuronal nicotinic, beta polypeptide 2; CLCN2, chloride channel 2; CNTN2, contactin 2; CPA6, carboxypeptidase A6; CSTB, cystatin B; DEPDC5, DEP domain-containing protein 5; DNM1, dynamin 1; DOCK7, dedicator of cytokinesis 7; EEF1A2, eukaryotic translation elongation factor 1, alpha-2; EFHC1, EF-hand domain (C-terminal)-containing protein 1; EPM2A, EPM2A gene, encodes laforin; FGF12, fibroblast growth factor 12; FRRS1L, ferric chelate reductase 1-like; GABRA1, gamma-aminobutyric acid receptor, alpha-1; GABRB1, gammaaminobutyric acid receptor, beta-1; GABRB3, gamma-aminobutyric acid receptor, beta-3; GABRD, gamma-aminobutyric acid receptor, delta; GABRG2, gamma-aminobutyric acid receptor, gamma-2; GAL, galanin; GNAO1, guanine nucleotide-binding protein, alpha-activating activity polypeptide O; GOSR2, golgi snap receptor complex member 2; GPR98, G protein-coupled receptor 98; GRIN2A, glutamate receptor, ionotropic, N-methyl-D-aspartate, subunit 2A; GRIN2B, glutamate receptor, ionotropic, N-methyl-Daspartate, subunit 2B; GRIN2D, glutamate receptor, ionotropic, N-methyl-D-aspartate, subunit 2D; GUF1, GUF1 GTPase, S. cerevisiae, homolog of; HCN1, hyperpolarizationactivated cyclic nucleotide-gated potassium channel 1; ITPA, inosine triphosphatase; KCNA2, potassium channel, voltage-gated, shaker-related subfamily, member 2; KCNB1, potassium channel, voltage-gated, shab-related subfamily, member 1; KCNC1, potassium channel, voltage-gated, shaw-related subfamily, member 1; KCNMA1, potassium channel, calcium-activated, large conductance, subfamily M, alpha member 1; KCNQ2, potassium channel, voltage-gated, KQT-like subfamily, member 2; KCNQ3, potassium channel, voltage-gated, KQT-like subfamily, member 3; KCNT1, potassium channel, subfamily T, member 1; KCTD7, potassium channel tetramerization domain-containing protein 7;
LGI1, leucine-rich gene, glioma-inactivated, 1; LMNB2, lamin B2; NECAP1, NECAP endocytosis-associated protein 1; NHLRC1, NHL knowledge on the role played by specific mutations in epilepsy and the mechanisms underlying epileptogenesis.
Methods
To obtain a comprehensive list of genes associated with epilepsy, a thorough search of online databases was conducted. Briefly, we searched the Online Mendelian Inheritance in Man database (OMIM, http://www.ncbi.nlm.nih.gov/omim/) with the following query terms: "epilepsy/epilepsies/epileptic" or "seizure/ seizures." We then crosschecked the findings with the results from the searches performed on the Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ac/index.php) and the EpilepsyGene database (http://61.152.91.49/EpilepsyGene/). Additionally, recent publications relevant to epilepsy were searched on PubMed (http://www.ncbi.nlm.nih.gov/pubmed/).
More than 2000 items were retrieved from the OMIM database. These items were further analyzed through thorough reading and double-checked manually by two experts in the field of epilepsy. The items related to epilepsy and well-characterized gene mutations were included. We used the following criteria to exclude articles from the analysis: (1) clinical genetic reports without definite molecular genetic confirmation, (2) linkage analysis without identification of specific genes, (3) genomic rearrangement without the causative gene defined, (4) clinical syndrome potentially related to epilepsy; however, the patients with epilepsy were not subjected to a genetic test. Finally, 693 genes were identified to be associated with epilepsy. The phenotypes of these genes exhibit a large variability in epilepsy and other clinical manifestations. According to the manifestation of epilepsy in phenotypes, these genes were divided into 3 categories: (1) epilepsy genes, i.e., genes that only cause epilepsies or syndromes with epilepsy as the core symptom; (2) neurodevelopment-associated epilepsy genes, i.e., genes associated with gross brain developmental malformations and epilepsies; and (3) epilepsy-related genes, i.e., genes associated with gross physical, or other systemic abnormalities and accompanied by epilepsy or seizures.
After crosschecking the HGMD and EpilepsyGene databases, we found 247 additional genes, not present in the OMIM database, potentially associated with epilepsy. We did not include the 248 genes that were presented in the EpilepsyGene database but were not described to be associated with epilepsy in the original report [7] . Furthermore, considering that some of the genes which have been recently reported to be involved in epilepsy may not be present in any of the three databases, we searched PubMed for recent publications (i.e., since 2014) relevant to epilepsy. This last search yielded 37 more genes potentially associated with epilepsy.
Results

Epilepsy genes
Based on the results from the search in the OMIM database, 84 genes were classified as epilepsy genes. Mutations in these genes cause pure or relatively pure epilepsies, or syndromes with epilepsy as the core symptom. This category also includes genes that may be associated with multiple phenotypes other than epilepsy or seizures; however, an individual with mutations in these genes may present only epilepsy or seizures. For example, PRRT2 mutations are associated with several clinical syndromes such as paroxysmal dyskinesia, infantile convulsions with paroxysmal choreoathetosis, and benign familial infantile seizures [8] . Although paroxysmal dyskinesia is the main symptom in the Table 2 Functional categories of the epilepsy genes.
Encoded protein function
Gene and phenotype (OMIM phenotype)
Ion channel
Sodium channel
Bold italics, with multiple functional classifications. AIES, Amish infantile epilepsy syndrome; BFIS, benign familial infantile seizures; BFNS, benign familial neonatal seizures; CAE, childhood absence epilepsy; COEE, childhoodonset epileptic encephalopathy; DS, Dravet syndrome; EIEE, early infantile epileptic encephalo-pathy; EPD, pyridoxine-dependent epilepsy; FAME, familial adult myoclonic epilepsy; FESD, focal epilepsy and speech disorder with or without mental retardation; FFEVF, familial focal epilepsy with variable foci; FFS, familial febrile seizures; FIME, familial infantile myoclonic epilepsy; FTLE, familial temporal lobe epilepsy; GEFS+, generalized epilepsy with febrile seizures plus; GEPD, generalized epilepsy and paroxysmal dyskinesia; IGE, idiopathic generalized epilepsy; JAE, juvenile absence epilepsy; JME, juvenile myoclonic epilepsy; MAE, myoclonic-atonic epilepsy; NFLE, nocturnal frontal lobe epilepsy; PME, progressive myoclonic epilepsy; PNPOD, pyridoxamine 5'-phosphate oxidase deficiency. a Description on phenotype was modified after retraction of the initial report. majority of patients, there are cases of only benign familial infantile seizures in individuals harboring this mutation. To facilitate the search for causative genes, we present a summary of these genes according to their phenotypes and sorted according to their onset age ( Table 1) . The spectrum of epilepsy caused by gene mutations covers 23 epileptic phenotypes, ranging from the mild form of benign familial infantile seizures to the extremely severe form of early infantile epileptic encephalopathy (EIEE). More than one causative gene has been identified in 14 epileptic phenotypes. EIEE was shown to be associated with mutations in 42 genes. Progressive myoclonic epilepsy was associated with 11 pathogenic genes. Other common phenotypes with multiple genetic causes are mostly represented by idiopathic epilepsies including childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and idiopathic generalized epilepsy. In contrast, only a single causative gene has been identified in 9 epileptic phenotypes. However, except for few cases with definite one-to-one epilepsy to gene correlation such as myoclonic-atonic epilepsy and SLC6A1, more than one genetic cause is generally expected to be identified in most of the phenotypes. For instance, CHRNA4 was initially identified as the only pathogenic gene of nocturnal frontal lobe epilepsy [9] ; however, later studies demonstrated that CHRNB2, CHRNA2, and KCNT1 were also associated with this type of epilepsy [10] [11] [12] . The causative genes produce large variation in the inheritance pattern of the genetic epilepsies. The inheritance pattern has commonly been classified into dominant (autosomal or X-linked) or recessive (autosomal or X-linked) inheritance. However, recent studies have identified epilepsy genes with undefined inheritance, including genes with de novo mutations. De novo mutations may be associated with autosome dominant genetic disorders, such as the spectrum of epilepsies with febrile seizures plus caused by SCN1A mutations, typically in Dravet syndrome [2] . De novo mutations have been frequently identified in epileptic encephalopathies [13] [14] [15] [16] . However, as many of these children with neurodisability did not reproduce, it was unclear as to whether these are de novo dominant mutations. An exception is that EIEE caused by PCDH19 mutations included de novo mutations, but presented an inheritance of neither X-linked dominant nor recessive. EIEE displayed heterogeneity in both the genetic cause and the inheritance pattern. It is noteworthy that epileptic encephalopathies encompass several clinical subtypes such as the Lennox-Gastaut syndrome, the West syndrome, and the Landau-Kleffner syndrome. We failed to identify genetic information for each of the syndromes separately owing to the lack of detailed information available in OMIM or publications.
To better understand the molecular characteristics of the products of epilepsy genes, we grouped the genes according to the protein function ( Table 2 ). The most common epilepsy genes were ion-channel genes, which account for 28 of the 84 epilepsy genes, indicating that ion-channel genes may play an important role in epilepsy. Mutations in ion-channel genes produce a variety of epilepsies with phenotypes ranging from mild to severe. Mutations in enzyme/enzyme-modulator genes ranked as the second cause (25/84); these mainly caused the severe form of epilepsy, except mutations in CPA6 gene which cause relatively mild familial temporal-lobe epilepsy and familial febrile seizures [17] . The remaining genes included in the analysis are involved in transport, receptor binding, cell adhesion, signal transduction/molecule, membrane trafficking, cytoskeleton, nucleic acid binding, and other unknown functions. Table 2 shows that 17 epilepsy genes are involved in more than one epileptic phenotype. Theoretically, the impairment caused by mutations in a gene may vary in severity, thereby correlating with the severity of the phenotype. This is typically observed in epilepsies caused by SCN1A mutations which produce a spectrum of phenotypes ranging from the mild form of generalized epilepsies with febrile seizures plus, or pure febrile seizures [18, 19] , to the extremely severe form of the Dravet syndrome [20, 21] , and there was a correlation between the genotypes or function alterations (functional-type or funotype) and phenotypes [2] . Similar correlations have been observed in epilepsies caused by mutations in KCNQ2 and GABRA1. For some genes, such as SCN2A and SCN8A, although mild and severe cases have been reported following their mutations, a correlation between genotype (or funotype) and phenotype has not been found yet. Thus, the pathogenic role played by these genes in epilepsy requires further investigation.
Neurodevelopment-associated epilepsy genes
In total, 73 genes were classified as neurodevelopmentassociated epilepsy genes. Mutations in these genes produce gross neurodevelopmental malformations and epilepsy, which may vary in severity. Mutations in some genes, such as TSC1 and TSC2, cause the tuberous sclerosis, which may be accompanied by severe epilepsy [3, 4] . Other genes, such as TUBB3 and WDR62, are associated with characteristic brain developmental malformations but infrequent epileptic seizures [22, 23] .
With the development of neuroimaging techniques, identification of the neurodevelopmental malformation provides critical evidences for the diagnosis and classification of the phenotype. We reviewed these genes according to the localization of brain malformations, which vary from focal (or multifocal) to general brain malformation. These brain malformations may be accompanied by physical or other systemic abnormalities (Table 3) . It should be noted that gene mutations have also been identified in cases with subtle or undetectable malformations.
From the gene-function point of view (Table 4) , enzyme/ enzyme modulator genes represent a large fraction of neurodevelopment-associated epilepsy genes (24/73), suggesting that these genes play a significant role in neurodevelopment and epileptogenesis. Genes encoding cytoskeletal molecules appeared also frequently (15/73). The remaining genes are involved in cell adhesion, extracellular matrix, membrane structure, membrane trafficking, or other unknown functions. In contrast, we did not come across any ion-channel gene. These data may further our knowledge on the pathogenic mechanisms of neurodevelopment and epilepsies.
Epilepsy-related genes
From the OMIM database, 536 genes were recognized as epilepsy-related genes. These genes are associated with diseases presenting gross physical, or other systemic, abnormalities that are Table 5 ) including those that directly affect the cerebral neurons, such as the neuronal ceroid lipofuscinosis, in which epileptic seizure is a prominent feature; and those that may be indirectly related to brain function, such as the spinal muscular atrophy, in which epileptic seizure is inconstant. The characteristic clinical features of these disorders, beside epilepsy, usually provide useful clues for the clinical diagnosis and prompt for further genetic tests.
Potential epilepsy-associated genes
We found 247 additional genes by crosschecking our findings with those from the HGMD and the EpilepsyGene databases and 37 more genes by searching through recent publications (Table 6 ). These genes are reported to be potentially associated with epilepsy; however, they are currently not present in the OMIM database. Their associations with epilepsy warrant further verification in most of the cases. For instance, CUX1 and MCM9 were listed in the EpilepsyGene database. Mutations in CUX1, MCM9, and KCNT1 were identified in a patient with malignant migrating partial seizures of infancy. KCNT1 is an epilepsy gene and the KCNT1 mutation (c.2800G>A, p.Ala934Thr) identified in this patient has been experimentally proved to cause functional alternations [24] . Thus, the role of CUX1 and MCM9 in epilepsy ACMSD, ACOT7, ADAM22, AKT3, CBL, CHD1L, CHD3, CHD4, COX1, COX3, CP, CSNK1G1, CYP26C1, DGKD, DNM3, FASN, FBXO28, GBE1, HCK,  HDAC4, HECW2, HS2ST1, HUWE1, INPP4A, KARS, KDM6A, KIAA1456, MAGI2, MAN2A2, MANBA, MAPK10, MCM9, ME2, MPP7, MRI1,  MTMR11, ND1, ND4, ND5, NEDD4, NEDD4L, NEU1, OPA1, PARK2, PHF8, PIGQ, PNPT1, PRKX, PTPN23, SGK223, ST8SIA2, STK11, TK2, TNK2,  TRIM8, TRMT44, UBR5, WHSC1, C7orf55, DIP2C, FLG, GRIP1, HEG1, ITGB1BP1, KIAA2022, LRFN5, NCKAP5, NELL1, NGFRAP1, NKAIN3,  NOL11, PIK3AP1, PODXL, PRICKLE2, PRRC2B, RB1, RD3, SEZ6, SHANK1, SKI, SLC7A6OS, SQSTM1, ST5, ST7, STYXL1, TBL1XR1, TENM2,  TMEM139, TSPYL4, TTN, YWHAE, ZFYVE20 Bold italics, with multiple functional classifications.
has been questioned. In contrast, mutations in some genes, such as SCN3A, GABRA6, and KCNH5, have been repeatedly reported in patients with epilepsy [25] [26] [27] [28] [29] [30] , and functional alterations induced by these mutations have been experimentally confirmed [26, 28, 30] .
Discussion
Here, we review all genes potentially associated with epilepsy, and present a summary of these genes according to the manifestation of epilepsy in the phenotype. These genes include epilepsy genes, neurodevelopment-associated epilepsy genes, and epilepsy-related genes. These integrated data represent a framework of epilepsy-associated genes that may be used for the following: (1) considering genetic tests in clinical practice and (2) evaluating the results of these tests. However, we must acknowledge that an endeavour such as this runs the risk of being incomplete, since there continue to be identification of novel epilepsy-associated genes in the following days.
Eighty-four genes have been considered as epilepsy genes. However, it should be noted that although these genes are associated with epilepsies, the pathogenic role played by each gene may differ according to the phenotype. For instance, both SCN1A and SCN9A are reported to be associated with the Dravet syndrome. Mutations in SCN1A are responsible for approximately 70-80% of the cases with Dravet syndrome [2, 20, 31] , and the genotype (funotype)-phenotype correlations have been documented [2] . In contrast, SCN9A may play a minor role and was suggested as a modifier gene in Dravet syndrome [32] . Generally, an epileptic syndrome may have several genetic causes. Idiopathic epilepsies are believed to be caused by genetic abnormalities. Mutations in several genes have been identified in idiopathic epilepsies, such as GABRG2, GABRB3, CACNA1H, and GABRA1 in childhood absence epilepsy. However, the pathogenic role of each gene in idiopathic epilepsy warrants further experimental and clinical studies. From a practical point of view, except few genes like SCN1A, the frequency of gene mutation in an epileptic syndrome was not determined for most of the epilepsy genes. On the other hand, it has been frequently observed that an epilepsy gene may lead to several phenotypes, i.e., a spectrum of phenotype. Theoretically, due to the distinct function of the gene, phenotypes within the spectrum would share features in common, typically shown in the spectrum of epilepsy caused by SCN1A mutations. SCN1A mutations are associated with Dravet syndrome, partial epilepsy with antecedent febrile seizures, and generalized epilepsies with febrile seizures plus. The antecedent febrile seizure is the common feature in most of the cases and is a critical clue in clinical diagnosis and management [2, 33] .
Seventy-three genes have been considered as neurodevelopment-associated genes and 536 genes have been listed as epilepsyrelated genes. The apparent neurodevelopmental malformation and gross physical or systemic abnormalities accompanied would provide critical evidences for the diagnosis and clues for designing cost-effective genetic-testing strategy for a specific target patient population. Two hundred and eighty-four genes are putatively associated with epilepsy. Although further verifications are required, new epilepsy genes are expected to be identified. The present summary of gene functions and their associations with epilepsy will serve as the basis for considering future studies, and it will further our understanding of the underlying genetic mechanisms of epilepsy.
Conflicts of interest
All authors declare that they have no conflicts of interest concerning this article.
